EUVIMEDEUVIMED entdecken
Crossref

Allosteric Inhibition of PKMYT1 Induces a Unique, Inactive ATP Binding Site Conformation

Noah B Herrington iD, Susmita Khamrui, Yihan Zhao, Carisse Lansiquot iD, Ruoxi Wu, Gaurav Pandey, Michael B Lazarus iD, Avner Schlessinger iD

Journal of the American Chemical Society · 2026

DOI: 10.1021/jacs.6c05178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2026. Verfasst von Noah B Herrington und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States. Hauptthemen laut MEDLINE: Adenosine Triphosphate, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases, Membrane Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: NIGMS NIH HHS, U.S. Department of Health and Human Services, U.S. Department of Energy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The protein kinase PKMYT1 regulates a key cell cycle checkpoint as part of the cell’s DNA-damage repair response, but in cancer, this function can promote tumor cell survival through avoiding mitotic catastrophe. PKMYT1 has been linked to a variety of cancer types, including breast, gastric, and nonsmall cell lung cancers, as well as kidney renal clear cell carcinoma, making it an important therapeutic target. However, potent and selective small-molecule inhibitors of PKMYT1 are scarce, and its specific biological role in tumor proliferation remains understudied. Here, we report the discovery and characterization of a novel PKMYT1 inhibitor, P29, bound to a previously unknown allosteric site. Structural and kinetic data reveal that P29 induces a conformational rearrangement of the P-loop and inhibits PKMYT1 through a mixed ATP competitive and noncompetitive mechanism. A closely related analogue, P32, exhibits selectivity and enhanced potency and engages PKMYT1 in cells. Surprisingly, however, it binds in the ATP binding pocket, demonstrating that subtle chemical modifications can shift binding mode and mechanism of inhibition. Furthermore, computational analysis using structural modeling methods, including AlphaFold2, AlphaFold3, Boltz-2, as well as unbiased MD simulations, indicates that these approaches are limited in their ability to capture this inhibitor-induced cryptic binding site and conformational change. Our study identifies an underexplored allosteric site in PKMYT1 and establishes a new avenue for the rational design of selective kinase inhibitors targeting a cryptic binding site in this emerging drug target. These findings also reveal intrinsic challenges in the computational discovery of noncanonical kinase binding sites and underscore the necessity of integrating computational modeling with experimental testing using structural and functional approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine TriphosphateProtein Kinase InhibitorsProtein Serine-Threonine KinasesMembrane ProteinsHumansBinding SitesAllosteric RegulationModels, MolecularProtein ConformationAllosteric SiteProtein-Tyrosine Kinases

Substanzen

Adenosine TriphosphatePKMYT1 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesMembrane ProteinsProtein-Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • AI Small Molecule Drug Discovery Center, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.

ORCID-Profile: Noah B Herrington, Carisse Lansiquot, Michael B Lazarus, Avner Schlessinger

Förderung

  • NIGMS NIH HHS
  • U.S. Department of Health and Human Services
  • U.S. Department of Energy

Zitieren

APA

Herrington, N. B., Khamrui, S., Zhao, Y., Lansiquot, C., Wu, R., Pandey, G., Lazarus, M. B., & Schlessinger, A. (2026). Allosteric Inhibition of PKMYT1 Induces a Unique, Inactive ATP Binding Site Conformation. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6c05178

Vancouver

Herrington NB, Khamrui S, Zhao Y, Lansiquot C, Wu R, Pandey G, et al. Allosteric Inhibition of PKMYT1 Induces a Unique, Inactive ATP Binding Site Conformation. Journal of the American Chemical Society. 2026. doi:10.1021/jacs.6c05178

BibTeX
@article{Herrington2026,
  author = {Herrington, Noah B and Khamrui, Susmita and Zhao, Yihan and Lansiquot, Carisse and Wu, Ruoxi and Pandey, Gaurav and Lazarus, Michael B and Schlessinger, Avner},
  title = {Allosteric Inhibition of PKMYT1 Induces a Unique, Inactive ATP Binding Site Conformation},
  journal = {Journal of the American Chemical Society},
  year = {2026},
  doi = {10.1021/jacs.6c05178}
}
Kostenlos starten →